Contineum Therapeutics CSO Sells Stock Via Pre-Arranged Plan Amid Clinical Progress
Daniel Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc., recently sold shares through a pre-arranged trading plan. This transaction occurred amidst several significant updates regarding the company's clinical pipeline, including topline data release for PIPE-791 and reiterated Buy ratings from analysts.